UT-MD Anderson Cancer Center: Patients With Refractory Metastatic Colorectal Cancer Experience Survival Benefits With Fruquintinib
June 16, 2023
June 16, 2023
HOUSTON, Texas, June 16 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 15, 2023:
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, . . .
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, . . .